Animas Corporation (NASDAQ:PUMP) management today increased its revenue guidance for 2004 and provided initial guidance for 2005.
The company also announced that it had received 510(k) clearance in December 2004 from the Food and Drug Administration to market the IR 1250 pump. “We are dedicated to making diabetes management easier for both the patient and the healthcare provider. This product is an important step toward achieving that goal, and receipt of this clearance will allow us to launch this product during this quarter,” said President and CEO Kathy Crothall.